PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Trial aims to improve treatment for newborns with life-threatening sepsis

An international clinical trial co-led by UCL (University College London) researchers will evaluate much-needed new antibiotic combinations for newborn babies with sepsis.

Trial aims to improve treatment for newborns with life-threatening sepsis
2023-05-23
(Press-News.org) An international clinical trial co-led by UCL (University College London) researchers will evaluate much-needed new antibiotic combinations for newborn babies with sepsis.

The trial, which has started in three public hospitals in South Africa and Kenya, will be expanded to other countries and regions in 2024, with a target of recruiting up to 3,000 newborns overall.

The NeoSep1 trial will evaluate new combinations of generic antibiotics and compare them to existing treatment regimens that are often used in newborn babies with suspected neonatal sepsis.

Chris Hani Baragwanath Academic Hospital in Johannesburg, Tygerberg Hospital in Cape Town and KEMRI, Kilifi County Hospital in Kenya are involved in the initial stage of the clinical trial.

Neonatal sepsis, a life-threatening infection, affects up to 3 million babies a year globally. It has become increasingly challenging as about 40% of infections are reported to be resistant to standard antibiotic treatments. Over 214,000 newborn babies die of drug-resistant neonatal sepsis every year, mostly in low- and middle-income countries (LMICs).  

The trial is sponsored by the Global Antibiotic Research and Development Partnership (GARDP) in collaboration with the Medical Research Council Clinical Trials Unit at UCL (MRC CTU at UCL); St George’s, University of London; and Penta.

“Many babies are dying because of limited treatment options. The NeoSep1 trial is an opportunity to shift this trajectory by identifying new antibiotic combinations that we can tailor to treat neonatal sepsis in settings where there is widespread resistance to current recommended options. This is vital if we are going to address the impact of antimicrobial resistance on the burden of disease related to neonatal sepsis,” said Seamus O’Brien, Director of Research and Development at GARDP.

The trial will rank the safety and efficacy of three new combinations of older antibiotics (fosfomycin-amikacin, flomoxef-amikacin, and flomoxef-fosfomycin) against the current standard of care. It will also assess and validate the doses of two antibiotics (fosfomycin and flomoxef) for use in newborns.

A key goal is to find out whether some antibiotic treatments perform better than others for the empiric treatment of babies with neonatal sepsis, particularly in LMICs where highly resistant bacteria are common. The trial will also consider how these combination treatments can best be used in hospital settings with varying levels of antibiotic resistance.

A new way of comparing antibiotic treatments with each other, called the Personalised Randomised Controlled Trial (PRACTical) design, will be used. The novelty of this design is that it allows researchers to compare many antibiotic treatments for neonatal sepsis. It will also enable doctors to choose treatment regimens that are likely to work well for newborns in their particular hospital settings.

“The development pipeline for new antibiotic treatments is limited and the lack of a universal, effective standard of care creates huge challenges in conducting research to tackle neonatal sepsis. Novel trial designs such as the PRACTical design have been specifically developed to address these challenges in important public health emergencies such as neonatal sepsis,” said Sarah Walker, Professor of Medical Statistics and Epidemiology at the MRC CTU at UCL.

The NeoSep1 trial builds on findings from a global observational study of sepsis in newborn babies, conducted by GARDP and partners in 19 hospitals in 11 countries from 2018 to 2020. GARDP published a report on the study in 2022.

The study found a worryingly wide variation in treatment and frequent switching of antibiotics because of high resistance to treatments.  

“Newborns handle medicines very differently to older infants, children and adolescents. Premature or otherwise critically ill babies are at great risk of severe infection or sepsis because of their immature immune systems.  The types of bacteria causing newborn infections are not necessarily the same as those found in other patients. For these reasons, it is essential to investigate antibiotic treatments of newborns with sepsis,” said Dr Julia Bielicki, paediatrician and researcher in the Centre for Neonatal and Paediatric Infection at St George’s, University of London.

The trial aims to generate relevant and reliable evidence for doctors who need to make treatment decisions, especially in hospitals where there are high levels of antimicrobial resistance.

“We often have to treat babies with a combination of the antibiotics of last resort. On top of this we are not 100% sure about how to dose these drugs. We’re dealing with fragile newborns, so we need to be aware of the potential toxicity of the antibiotics and dosages we use. This trial will help in giving us confidence that we are delivering more effective treatment. This is critical as we want the best possible outcome for newborns in our care,” said Adrie Bekker, Principal Investigator for the NeoSep1 trial at Tygerberg Hospital, Cape Town, and Professor in the Division of Neonatology, Department of Paediatrics and Child Health at Stellenbosch University. 

“We need to treat newborn babies in our care promptly and effectively otherwise there is great risk that babies could die or are left with neurodevelopment impairment. Having the right antibiotics can make the difference between life and death. We are hoping the trial will provide robust evidence that the antibiotic combinations are safe and effective and that this will lead to a change in both WHO and local treatment guidelines,” said Christina Obiero, Principal Investigator for the NeoSep1 trial for the KEMRI-Wellcome Trust Research Programme at Kilifi County Hospital, Kenya.

END


[Attachments] See images for this press release:
Trial aims to improve treatment for newborns with life-threatening sepsis

ELSE PRESS RELEASES FROM THIS DATE:

Previous smallpox vaccine provides immunity to mpox

2023-05-23
Vaccines against smallpox given until the mid-1970s offer continuing cross-reactive immunity to mpox (previously known as monkeypox), researchers from Karolinska Institutet in Sweden report in a study published in the scientific journal Cell Host & Microbe. During last year’s mpox outbreak, the virus spread for the first time outside Africa, causing over 85,000 cases of the disease to date. Men who have sex with men account for the most infections, with a marked skew towards the young. The virus that causes mpox is what is known as an orthopoxvirus and is very similar to the virus that caused ...

Fever found to be most common non-respiratory feature of SARS-CoV-2 infection

Fever found to be most common non-respiratory feature of SARS-CoV-2 infection
2023-05-23
Session:  C58, Health Services Research in Diverse Settings Date and Time: 11:30 a.m. ET, Tuesday, May 23, 2023 Location:  WEWCC, Area 1, Hall C (Lower Level)   ATS 2023, Washington, DC – Fever was found to be the most common non-respiratory feature of infection with SARS-CoV-2, the virus that causes COVID-19, according to research published at the ATS 2023 International Conference.  The finding held true regardless of which COVID variant patients had, and whether or not they were fully vaccinated or not fully vaccinated. The researchers, who also looked at mortality risk, found that patients who were ...

International group of experts redefines concussions

2023-05-23
Doctors and other health-care providers have a new standard for diagnosing mild traumatic brain injury (TBI), thanks to a thorough process led by researchers from the University of B.C. and Harvard-affiliated Spaulding Rehabilitation Hospital. "We've achieved consensus across a diverse range of experts in developing these new diagnostic criteria,” said Dr. Noah Silverberg, associate professor in UBC’s department of psychology, member of the Djavad Mowafaghian Centre for Brain Health and Centre for Aging SMART at Vancouver Coastal Health, and co-lead of the project. “Our ...

USC Health System Board appoints Paul B. Rothman, MD, as board member

USC Health System Board appoints Paul B. Rothman, MD, as board member
2023-05-23
LOS ANGELES — Paul B. Rothman, MD, has been appointed as a member of the USC Health System Board, which provides strategic oversight and governance over Keck Medicine of USC and university clinical services.  Rothman, former CEO of Johns Hopkins Medicine and retired dean of medical faculty for the Johns Hopkins University School of Medicine, brings his leadership acumen as well as clinical and scientific expertise in rheumatology and molecular immunology to this advisory role.  “Paul ...

Diagnosis of type 1 diabetes after SARS-CoV-2 infection: Researchers find possible correlation

2023-05-23
Different studies have documented an increased incidence of type 1 diabetes during the COVID-19 pandemic. However, none of the studies distinguishes between children with and without SARS-CoV-2 infection. Researchers were now able to gain new insights: the KVB data set provides information on whether children diagnosed with type 1 diabetes previously had COVID-19. This allows an analysis of the temporal relationship between a COVID-19 diagnosis and the diagnosis of type 1 diabetes. Amongst the analyzed children without ...

RPI and Albany Medical College researchers awarded $3.3 million to improve breast cancer treatment using artificial intelligence

RPI and Albany Medical College researchers awarded $3.3 million to improve breast cancer treatment using artificial intelligence
2023-05-23
Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College were awarded a $3.3 million grant over five years by the National Cancer Institute to use artificial intelligence (AI) to improve targeted drug therapy in HER2-positive breast cancer treatment. HER2-positive breast cancer tends to grow and spread quickly, but targeted treatments improve outcomes. The research is being led by Xavier Intes, Rensselaer professor of biomedical engineering and co-director of the Center for Modeling, Simulation and Imaging in Medicine, and ...

Element creation in the lab deepens understanding of surface explosions on neutron stars

Element creation in the lab deepens understanding of surface explosions on neutron stars
2023-05-23
Led by Kelly Chipps of the Department of Energy’s Oak Ridge National Laboratory, scientists working in the lab have produced a signature nuclear reaction that occurs on the surface of a neutron star gobbling mass from a companion star. Their achievement improves understanding of stellar processes generating diverse nuclear isotopes. “Neutron stars are really fascinating from the points of view of both nuclear physics and astrophysics,” said ORNL nuclear astrophysicist Kelly Chipps, who led a study published in Physical Review Letters. “A deeper understanding of their dynamics may help reveal the cosmic ...

New treatment helps people stop addictive opioid painkillers used for chronic pain

2023-05-23
Programme of combined one-to-one and group support sessions was tested in landmark clinical trial After one year, one in five people were able to stop taking opioids without their pain increasing Experts say the new treatment is an alternative to opioid use and has potential to give patients better quality of life Researchers at the University of Warwick and The James Cook University Hospital, Middlesbrough have led a clinical trial, funded by the National Institute for Health and Care Research (NIHR), on a new treatment which can help people stop needing to use opioid painkillers to manage chronic pain. There are over 1 ...

CT scan best at predicting heart disease risk in middle age

2023-05-23
CHICAGO ---CT scans are better at predicting a middle-aged person’s risk for a heart disease, such as a heart attack, than genetics, reports a new Northwestern Medicine study.  “Finding the best way to identify who is at risk for developing heart disease can help determine what needs to be done to lower their risk,” said lead study author Dr. Sadiya Khan, an assistant professor of medicine and preventive medicine at Northwestern University Feinberg School of Medicine and a Northwestern Medicine cardiologist. “This finding can help doctors and patients in managing risk for heart disease, which is the leading cause ...

Study: Transcatheter mitral valve repair safe, successful

Study: Transcatheter mitral valve repair safe, successful
2023-05-23
Long-awaited outcomes data of transcatheter edge-to-edge procedures to repair patients’ leaky mitral valves revealed the minimally invasive procedure to be safe and effective in nearly 90% of patients, according to Cedars-Sinai physician-scientists. Their findings on the condition called degenerative mitral regurgitation were published today in the peer-reviewed Journal of the American Medical Association (JAMA), representing the largest study to date that examines outcomes for patients treated outside of a clinical trial with transcatheter edge-to-edge repair (TEER). “Treatment was successful in nearly nine out of every 10 patients in whom TEER was used to repair ...

LAST 30 PRESS RELEASES:

Link found between kneecap shape and debilitating joint disease

Generative AI tools like Pix2Pix–BicycleGAN are revolutionizing landscape design by enhancing masterplan generation and rendering

Expanding APAC presence, Insilico Medicine seals strategic collaboration on AI-driven mash therapy development with Korean Biotech Therasid Bioscience

When it comes to butterflies, people prefer pretty ones. That’s a problem for scientists.

UBC Okanagan study raises concerns about partner violence in queer relationships

Human-infecting parasite produces sterile soldiers like ants and termites

The unintended consequences of success against malaria

Taco-shaped arthropod from Royal Ontario Museum’s Burgess Shale fossils gives new insights into the history of the first mandibulates

Butterflies accumulate enough static electricity to attract pollen without contact, new research finds

Eyes for Love: Searching for light and a mate in the deep, dark sea, male dragonfishes grow larger eyes than the females they seek

PNNL scientists tap nation’s fastest computers to explore critical science questions

Peri-operative care of transgender and gender-diverse individuals: new guidance for clinicians and departments published

Clinical psychologist’s book addresses largely ignored problem: social anxiety

Researchers leveraging AI to train (robotic) dogs to respond to their masters

Drawing water from dry air

Combining trapped atoms and photonics for new quantum devices

A new way to make element 116 opens the door to heavier atoms

New genetic tool could identify drug targets for diseases associated with metabolic dysfunction

Plant Biologist Siobhan Brady named HHMI Investigator

Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy

Large language models don’t behave like people, even though we may expect them to

NREL researchers highlight opportunities for manufacturing perovskite solar panels with a long-term vision

Top Medicare advantage plans less available in disadvantaged areas

Better carbon storage better carbon storage with stacked geology with stacked geology

Sharp temperature reduction for quantum dots in polymer by highly efficient heat dissipation pathways

UAF researcher creates way to detect elusive volcanic vibrations

Lissajous pattern multi-pass cell: Enhancing high sensitivity and simultaneous dual-gas LITES sensing

Asexual reproduction usually leads to a lack of genetic diversity. Not for these ants.

Mini lungs make major COVID-19 discoveries possible

Exploratory analysis associates HIV drug abacavir with elevated cardiovascular disease risk in large global trial

[Press-News.org] Trial aims to improve treatment for newborns with life-threatening sepsis
An international clinical trial co-led by UCL (University College London) researchers will evaluate much-needed new antibiotic combinations for newborn babies with sepsis.